The National Health Service in England has announced that it will fund Kalydeco for all patients aged 6 and over with the G551D mutation with effect from 1 January 2013.
Decisions on funding in Scotland, Northern Ireland and Wales (all of whcih have separate health systems) are awaited.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
